Education
About Us
Working with TipRanks
Follow Us
Molecular Partners AG (CH:MOLN)
:MOLN
Top Page
Molecular Partners AG
(OTC:MOLN)
Rating:46Neutral
Price Target:
CHF3.00
▲(3.45% Upside)
Positive Factors
Financial performance
2024 revenue of CHF 5MM and non-GAAP loss per share of CHF 1.59 was better than expected.
Financial position
The company has a solid cash position and building momentum behind innovative pipeline programs with broad potential.
Pipeline development
Key programs are on track, with MP0533 dosing in cohort 9 of its Phase I AML trial ongoing and cohort 10 being planned.
Negative Factors
Workforce reduction
A workforce reduction program is being implemented.
Molecular Partners AG (MOLN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
$117.09M
Dividend YieldN/A
Average Volume (3M)13.13K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth-91.34%
EPS Growth-2.84%
CountryCH
Employees158
SectorHealthcare
Sector Strength53
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.55
Shares Outstanding40,374,640
10 Day Avg. Volume11,867
30 Day Avg. Volume13,133
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.03
Enterprise Value/Revenue4.80
Enterprise Value/Gross Profit-0.30
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$9.25Price Target Upside218.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Molecular Partners AG Business Overview & Revenue Model
Company DescriptionMolecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
How the Company Makes MoneyMolecular Partners AG generates revenue through multiple streams, including licensing agreements, collaborations with pharmaceutical companies, and potential milestone payments associated with the development of their therapeutic candidates. The company enters into partnerships to leverage its DARPins technology for developing novel therapeutics, which can lead to upfront payments and royalties on future sales. Additionally, the company may receive milestone payments as its partnered products progress through various stages of clinical development. Their revenue model is heavily dependent on successful clinical trials and the eventual commercialization of its drug candidates.
Molecular Partners AG Earnings Call Summary
Earnings Call Date:Aug 25, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Mar 18, 2026
Earnings Call Sentiment Positive
Molecular Partners demonstrated significant progress in advancing their pipeline, particularly with the radio DARPin franchise and T cell engager 533, while maintaining a strong financial position. However, the discontinuation of the Novartis collaboration and resulting revenue impact were notable drawbacks.Q4-2024 Updates
Positive Updates
Successful Execution of 2024 Program Goals
Molecular Partners advanced their radio DARPin franchise with the lead compound DLL3 targeting 712 passing all IND-enabling studies, ready for clinical trials. They selected mesothelin as a new target and expanded their collaboration with Orano Med, securing 10 slots for Lead-212 isotope.
Positive Financial Health
The company ended 2024 with a cash balance of CHF 149 million, which supports operations into 2027. They raised CHF 20 million through financing, maintaining a solid financial base with no debt.
Encouraging Clinical Results and Pipeline Progression
The T cell engager 533 showed significant improvements in efficacy with new dosing strategies, resulting in 3 complete responses out of 8 patients treated past day 12.
Negative Updates
Novartis Collaboration Setback
The collaboration with Novartis was not continued as the targets did not progress as expected. This decision was mutual and based on strategic interests.
Revenue Decline from Novartis Collaboration
Revenue decreased as 2024 recognized the last part of the upfront payment from the Novartis collaboration, with no further revenue expected from this source.
Company Guidance
During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several notable metrics and guidance were provided. For the fiscal year 2024, the company reported revenues of CHF 5 million, exclusively from the Novartis collaboration. Operating expenses were CHF 66 million, within the guidance range of CHF 65 million to CHF 70 million, with 74% allocated to R&D. The net financial result benefited from high interest rates, contributing to an end-of-year cash balance of CHF 149 million, down from CHF 187 million the previous year, resulting in a cash burn of CHF 54 million. Looking ahead to 2025, Molecular Partners anticipates operating expenses between CHF 55 million and CHF 65 million, excluding potential partnership payments. The company is focused on advancing its radio DARPin programs, particularly MP0712, with expectations to start clinical trials and provide initial imaging data by the end of the year, while also progressing with its T cell engager program, MP0533, in AML, with new dosing amendments and outcomes expected by year-end.Molecular Partners AG Financial Statement Overview
Summary
Molecular Partners AG faces financial challenges with declining revenues and persistent losses impacting profitability. While the balance sheet remains relatively strong with low leverage, cash flow issues highlight the need for operational improvements to enhance long-term sustainability.Income Statement
Molecular Partners AG has experienced significant revenue declines in recent years, with a sharp drop from 2022 to 2023. The company has negative net and EBIT margins, reflecting ongoing losses. The gross profit margin improved in 2024, but overall profitability remains a concern.40
Negative
Balance Sheet
The company maintains a solid equity position with a high equity ratio over several years. However, there is a significant reduction in stockholders' equity from 2022 to 2024. Debt levels are low relative to equity, indicating limited leverage risk.60
Neutral
Cash Flow
Despite a positive operating cash flow in 2022, cash flow has been negative in recent years. Free cash flow has deteriorated, reflecting ongoing cash burn. The company benefits from cash reserves, mitigating immediate liquidity concerns.50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 681.00K | 4.97M | 7.04M | 189.56M | 9.33M | 9.34M |
| Gross Profit | -10.74M | -42.53M | -40.81M | 138.81M | -46.39M | -46.73M |
| EBITDA | -62.51M | -51.63M | -59.52M | 117.50M | -60.66M | -59.58M |
| Net Income | -64.81M | -54.04M | -61.98M | 117.85M | -63.78M | -62.76M |
Balance Sheet | ||||||
| Total Assets | 124.25M | 158.53M | 198.35M | 262.26M | 172.67M | 187.55M |
| Cash, Cash Equivalents and Short-Term Investments | 114.49M | 149.44M | 186.89M | 249.14M | 132.81M | 173.72M |
| Total Debt | 1.84M | 2.44M | 3.65M | 4.85M | 6.04M | 7.22M |
| Total Liabilities | 17.59M | 16.89M | 21.92M | 27.09M | 65.38M | 80.33M |
| Stockholders Equity | 106.66M | 141.64M | 176.43M | 235.17M | 107.29M | 107.22M |
Cash Flow | ||||||
| Free Cash Flow | -57.60M | -59.97M | -59.81M | 117.15M | -92.26M | -30.67M |
| Operating Cash Flow | -56.66M | -59.25M | -59.01M | 118.57M | -90.95M | -28.98M |
| Investing Cash Flow | 59.66M | 40.49M | 44.64M | -101.12M | -22.24M | -21.75M |
| Financing Cash Flow | 14.46M | 14.43M | -1.17M | -1.57M | 50.58M | 113.20M |
Molecular Partners AG Technical Analysis
Negative
2.90
Price Trends
2.97
Negative
3.10
Negative
3.73
Negative
Market Momentum
-0.03
Negative
47.16
Neutral
31.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOLN, the sentiment is Negative. The current price of 2.9 is below the 20-day moving average (MA) of 2.92, below the 50-day MA of 2.97, and below the 200-day MA of 3.73, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.16 is Neutral, neither overbought nor oversold. The STOCH value of 31.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MOLN.
Molecular Partners AG Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.95B | -0.40 | -41.67% | 2.21% | 22.29% | -1.85% | |
51 Neutral | CHF642.58M | ― | ― | 67.18% | -480.10% | ||
46 Neutral | $117.09M | ― | -48.90% | ― | -91.34% | -2.84% | |
| ― | $215.84M | 11.40 | ― | ― | ― | ||
| ― | $231.29M | 2.70 | -93.91% | ― | ― | ― | |
| ― | $44.15M | ― | -40.91% | ― | ― | ― | |
| ― | CHF118.24M | 3.47 | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
CH:MOLN
Molecular Partners AG
2.90
-1.65
-36.26%
CH:IDIA
Idorsia Ltd
2.88
1.14
65.52%
NWPHF
Newron Pharmaceuticals SpA
9.36
0.00
0.00%
SPHDF
Santhera Pharmaceuticals Holding
17.55
5.85
50.00%
RLFTF
RELIEF THERAPEUTICS Holding
3.47
0.65
23.05%
CH:XLS
Xlife Sciences Ltd.
20.80
-5.10
-19.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.